Psyence Biomedical (PBM) Cash from Financing Activities (2023)
Psyence Biomedical (PBM) posted Cash from Financing Activities of -$245.8 million for Q3 2023, down 100.02% on a QoQ basis from $1172.9 billion in Q1 2023.
Powered by 
Analysis
Psyence Biomedical (PBM) Cash from Financing Activities (2023) Analysis & Trends
Psyence Biomedical has reported Cash from Financing Activities for 1 years, with the latest figure at -$245.8 million in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.47 Bn | 193.48 Bn | 7.24 Bn | -1.48 Bn |
| 2 | Gilead Sciences | 178.76 Bn | 175.58 Bn | 6.22 Bn | 2.34 Bn |
| 3 | Vertex Pharmaceuticals | 131.52 Bn | 123.67 Bn | 2.84 Bn | -426.70 Mn |
| 4 | Regeneron Pharmaceuticals | 81.91 Bn | 73.91 Bn | 3.93 Bn | -1.22 Bn |
| 5 | Argenx Se | 61.10 Bn | 55.91 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.44 Bn | 48.30 Bn | 52.00 Mn | 14.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.55 Bn | 30.24 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Biogen | 31.67 Bn | 30.39 Bn | 1.96 Bn | 1.30 Bn |
| 9 | Roivant Sciences | 29.63 Bn | 29.63 Bn | 1.16 Mn | -181.51 Mn |
| 10 | Psyence Biomedical | 2.63 Mn | 2.63 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | -245.81 Mn |
| Mar 31, 2023 | 1,172.92 Bn |